NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: Bevacizumab

First Posted Date: 2006-12-11

Last Posted Date: 2017-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00409565

Locations: 🇺🇸
UPMC / UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 1 locations

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Biological: Bevacizumab
Drug: Cisplatin
Drug: Fluorouracil
Radiation: Intensity-Modulated Radiation Therapy

First Posted Date: 2006-12-07

Last Posted Date: 2018-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00408694

Locations: 🇺🇸
AnMed Health Hospital, Anderson, South Carolina, United States
🇺🇸
Rutgers New Jersey Medical School, Newark, New Jersey, United States
🇺🇸
UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

and more 105 locations

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Ovarian Sarcoma
Ovarian Stromal Cancer
Recurrent Endometrial Carcinoma
Recurrent Ovarian Epithelial Cancer
Recurrent Ovarian Germ Cell Tumor
Stage III Endometrial Carcinoma
Stage III Ovarian Epithelial Cancer
Stage III Ovarian Germ Cell Tumor
Stage IV Endometrial Carcinoma
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: temsirolimus

First Posted Date: 2006-12-07

Last Posted Date: 2014-06-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT00408655

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: tandutinib
Other: laboratory biomarker analysis

First Posted Date: 2006-12-07

Last Posted Date: 2017-11-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00408902

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Phase 3

Completed

Conditions: T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Interventions: Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Asparaginase
Other: Laboratory Biomarker Analysis
Drug: Daunorubicin Hydrochloride
Drug: Leucovorin Calcium
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Dexamethasone
Drug: Pegaspargase
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Drug: Nelarabine
Drug: Vincristine Sulfate
Radiation: Radiation Therapy
Drug: Thioguanine

First Posted Date: 2006-12-05

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1895

Registration Number: NCT00408005

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Saint Jude Midwest Affiliate, Peoria, Illinois, United States

and more 212 locations

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Phase 2

Completed

Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Bladder Cancer
Squamous Cell Carcinoma of the Bladder
Stage III Bladder Cancer
Stage III Urethral Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Urethral Cancer Associated With Invasive Bladder Cancer
Adenocarcinoma of the Bladder
Distal Urethral Cancer

Interventions: Biological: ziv-aflibercept
Other: pharmacological study

First Posted Date: 2006-12-05

Last Posted Date: 2014-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT00407485

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: alvocidib
Drug: cytarabine
Drug: mitoxantrone hydrochloride

First Posted Date: 2006-12-05

Last Posted Date: 2015-08-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00407966

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Stage IV Rectal Cancer
Stage IV Colon Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer

Interventions: Drug: aflibercept

First Posted Date: 2006-12-05

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00407654

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Phase 3

Completed

Conditions: Vesicoureteral Reflux
Urinary Tract Infections

Interventions: Drug: Trimethoprim-Sulfamethoxazole
Drug: Placebo

First Posted Date: 2006-11-30

Last Posted Date: 2020-04-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 607

Registration Number: NCT00405704

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 16 locations

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-11-17

Last Posted Date: 2015-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT00400829

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer